Sanofi's story needs to be 'better told,' new CEO says

Paul Hudson, who took over from Olivier Brandicourt as company chief a month ago, is preparing to lay out his strategy for the French drugmaker.

By Ned Pagliarulo • Oct. 1, 2019

Novartis, Lilly drugs set new survival bar in breast cancer

Study results detailing the survival benefit to Kisqali and Verzenio could help persuade more doctors to prescribe the targeted drugs. 

By Ned Pagliarulo • Sept. 29, 2019

Explore the Trendline➔

Top 5 stories from BioPharma Dive

Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.

By BioPharma Dive staff

AstraZeneca, Merck strengthen lead in PARP drug class

AbbVie appears back on track with rival veliparib, but until it's approved Lynparza looks set to be a preferred option in first-line ovarian cancer.

By Jonathan Gardner • Sept. 28, 2019

Pfizer's Read to step down as chairman, handing role to CEO Bourla

Albert Bourla took over as CEO in January. Now, the company veteran will also replace Read as head of the pharma giant's board of directors.

By Andrew Dunn • Sept. 27, 2019

Pfizer's new JAK drug works, but class safety concerns linger

While effective, the class has come under regulatory scrutiny for increasing patients' risk of blood clots and cardiovascular events.

By Jacob Bell • Sept. 27, 2019

Novartis recall of generic Zantac expands to US

British drugmaker GlaxoSmithKline, meanwhile, said it would halt distribution of Zantac product in countries where it sells the heartburn drug.

By Kristin Jensen • Sept. 26, 2019

GSK to spend $120M on new manufacturing hub for drug pipeline

The investment is part of nearly $400 million the British pharma has spent since 2017 to build out its vaccine and specialty drug production in the U.S.

By Kristin Jensen • Sept. 26, 2019

Does disclosure of pharma payments harm patient trust in doctors?

A counterintuitive finding raises questions about how transparency can be better managed, University of Pennsylvania researcher Genevieve Kanter told BioPharma Dive.

By Andrew Dunn • Sept. 23, 2019

Merck, Pfizer execs explain how they tap sites for cancer trials

The decisions hinge on a trial's phase and tumor type but are also affected by certain medical experts and the companies' history with a site.

By Jacob Bell • Sept. 23, 2019

Is the future of diabetes treatment better drugs or better care?

Drug manufacturers are trying to push the boundaries of glucose control, but cost concerns could rein in ambitions.

By Jonathan Gardner • Sept. 23, 2019

Facing $4B in claims, Insys doubts ability to pay out via Chapter 11

The bankrupt opioid drugmaker disclosed it does not expect to be able to meet "by a wide margin" the more than 8,000 outstanding claims against it.

By Andrew Dunn • Sept. 20, 2019

The top drugs facing cuts under Pelosi's pricing plan

Democrats' plan would put pressure on top-sellers from Bristol-Myers Squibb, Regeneron and Merck & Co, among others.

By Jonathan Gardner • Sept. 20, 2019

J&J finds competitive edge with latest Erleada approval

The advantage may be short-lived, however, as a rival prostate cancer drug from Pfizer could notch a similar approval in the fourth quarter.

By Jacob Bell • Sept. 18, 2019

Ebola vaccine from Merck takes step toward US approval

As DRC's outbreak persists, Merck plans to increase supply of its experimental V920 drug, aiming to produce 650,000 doses over the next six to 18 months.

By Ned Pagliarulo • Sept. 17, 2019

Opioid giant Purdue files for bankruptcy to pay for sweeping settlement

The Chapter 11 filing is meant to facilitate a more than $10 billion agreement in principle that the company just reached with 24 states and five U.S. territories.

By Jacob Bell • Sept. 16, 2019

Novartis' strong MS results could pose challenge to Roche

Little used in cancer, ofatumumab could find a second life as a multiple sclerosis drug, posting data that show it convincingly beat out Aubagio. 

By Ned Pagliarulo • Sept. 13, 2019

Private equity firm to buy Sanofi's oldest plant in India

Advent International snagged Sanofi's generics unit for $2 billion last year. Now, that unit is ready to acquire the Indian plant for about $37 million.

By Kristin Jensen • Sept. 12, 2019

Mallinckrodt selling CDMO business for up to $250M

The deal gives needed cash to Mallinckrodt, which is under pressure for its role in the opioid epidemic, and provides another example of private equity's interest in contract manufacturing.

By Kristin Jensen • Sept. 12, 2019

Public trust in drugmakers is at an all-time low. Can biopharma recover?

Leaders are grappling with how to improve the industry's reputation at a time when the broader business world is under increased scrutiny.

By Andrew Dunn • Sept. 11, 2019

Drug companies pay for exclusive access to UK genetic data

Amgen, AstraZeneca, GSK and J&J will get nine months to pour over the first wave of whole genome data coming out of UK Biobank before the global research community gets a chance to look.

By Jacob Bell • Sept. 11, 2019

Sanofi paying Lexicon $260M to exit diabetes alliance

Lexicon had argued Sanofi violated the companies' contract when providing notice in July that it would terminate a research partnership on Zynquista.

By Ned Pagliarulo • Sept. 11, 2019

Medicare would negotiate prices for 250 drugs under House Democrats' plan

Speaker Nancy Pelosi's proposal also finds common ground with the president in pegging U.S. prices to an international index.

By Jonathan Gardner • Sept. 10, 2019

Biomarker data help Merck case for wide use of Keytruda combo

"In the setting of chemo combinations, it does not appear that PD-L1 or TMB influences the outcome," said Merck development head Roy Baynes.

By Ned Pagliarulo • Sept. 10, 2019

Pfizer touts successor to Prevnar 13

Phase 2 data showed Pfizer's experimental pneumococcal vaccine to be safe, boosting confidence in what Pfizer hopes will be a follow-on to Prevnar 13.

By Andrew Dunn • Sept. 9, 2019

After scandal, Novartis pledges faster action on data integrity

CEO Vas Narasimhan committed to informing the FDA within five business days of any credible data integrity issues tied to a pending drug application.

By Ned Pagliarulo • Sept. 9, 2019